NASDAQ:RDUS - Radius Health Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$15.78 -0.18 (-1.13 %)
(As of 12/16/2018 04:00 PM ET)
Previous Close$15.78
Today's Range$15.25 - $16.04
52-Week Range$14.52 - $41.16
Volume703,665 shs
Average Volume622,768 shs
Market Capitalization$718.62 million
P/E Ratio-2.72
Dividend YieldN/A
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer. The company has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:RDUS
Previous Symbol


Debt-to-Equity Ratio1.85
Current Ratio5.50
Quick Ratio5.39


Trailing P/E Ratio-2.72
Forward P/E Ratio-3.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.11 million
Price / Sales32.50
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.43 per share
Price / Book2.91


EPS (Most Recent Fiscal Year)($5.80)
Net Income$-254,230,000.00
Net Margins-346.67%
Return on Equity-140.79%
Return on Assets-61.07%


Outstanding Shares45,540,000
Market Cap$718.62 million

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

How were Radius Health's earnings last quarter?

Radius Health Inc (NASDAQ:RDUS) posted its earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($1.09) EPS for the quarter, beating the Zacks' consensus estimate of ($1.26) by $0.17. The biopharmaceutical company had revenue of $27.70 million for the quarter, compared to analysts' expectations of $26 million. Radius Health had a negative net margin of 346.67% and a negative return on equity of 140.79%. Radius Health's revenue for the quarter was up 105.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.31) earnings per share. View Radius Health's Earnings History.

When is Radius Health's next earnings date?

Radius Health is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Radius Health.

What guidance has Radius Health issued on next quarter's earnings?

Radius Health issued an update on its FY 2019 earnings guidance on Thursday, November, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $155-175 million, compared to the consensus revenue estimate of $166.66 million.Radius Health also updated its FY 2018 guidance to EPS.

What price target have analysts set for RDUS?

8 brokers have issued 12 month target prices for Radius Health's stock. Their forecasts range from $25.00 to $59.00. On average, they anticipate Radius Health's stock price to reach $48.1429 in the next year. This suggests a possible upside of 205.1% from the stock's current price. View Analyst Price Targets for Radius Health.

What is the consensus analysts' recommendation for Radius Health?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Radius Health.

What are Wall Street analysts saying about Radius Health stock?

Here are some recent quotes from research analysts about Radius Health stock:
  • 1. According to Zacks Investment Research, "Radius got  a boost with the approval of lead drug Tymlos. Sales of Tymlos continue to gain traction. Total prescriptions accounted for 22% of total U.S. anabolic osteoporosis market (based on Patient Months on Therapy, TRx PMOT) in the quarter. Tymlos is expected to be covered for approximately 274 million insured lives, representing approximately 95% of U.S. commercial and 64% of Medicare insured lives effective Jan 1, 2019. However, Radius suffered a setback when the CHMP communicated a negative trend vote for the MAA following a re-examination procedure of lead drug Tymlos. Thereafter, the CHMP communicated that it maintained its negative opinion on the MAA at its formal final vote. While the market for postmenopausal osteoporosis provides significant commercial potential, it is pretty crowded given the presence of products like Amgen’s Prolia and Lilly’s Forteo. Shares have underperformed the industry so far." (12/11/2018)
  • 2. Cantor Fitzgerald analysts commented, "TYMLOS Growing the Market. RDUS reported 1Q18 sales of $14.5 mln, up from $7.7 in the prior quarter. The launch is modest, which is not surprising given the specialty market and reimbursement/coverage ramp. What is a positive dynamic, in our view, is the market growth overall, with TYMLOS both capturing market share and growing the market overall for anabolics." (5/11/2018)

Has Radius Health been receiving favorable news coverage?

News coverage about RDUS stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Radius Health earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are some of Radius Health's key competitors?

Who are Radius Health's key executives?

Radius Health's management team includes the folowing people:
  • Mr. Jesper Høiland, Pres, CEO & Director (Age 58)
  • Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 46)
  • Mr. Brent Hatzis-Schoch J.D., Sr. VP, Gen. Counsel & Sec. (Age 53)
  • Mr. Brian Nicholas Harvey, Advisor (Age 57)
  • Dr. Stavros C. Manolagas M.D., Ph.D., Co-Founder and Member of the Scientific Advisory Board

Who are Radius Health's major shareholders?

Radius Health's stock is owned by many different of retail and institutional investors. Top institutional investors include BB Biotech AG (14.47%), HealthCor Management L.P. (7.87%), Vanguard Group Inc. (7.84%), Vanguard Group Inc (7.84%), FMR LLC (2.57%) and Point72 Asset Management L.P. (2.20%). Company insiders that own Radius Health stock include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland and Jose Carmona. View Institutional Ownership Trends for Radius Health.

Which major investors are selling Radius Health stock?

RDUS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Pictet Asset Management Ltd., Credit Suisse AG, Point72 Asset Management L.P., Franklin Resources Inc., Wells Fargo & Company MN, Highland Capital Management LP and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Radius Health.

Which major investors are buying Radius Health stock?

RDUS stock was purchased by a variety of institutional investors in the last quarter, including HealthCor Management L.P., BB Biotech AG, Man Group plc, Teachers Advisors LLC, Rubric Capital Management LP, DekaBank Deutsche Girozentrale, Laurion Capital Management LP and Marshall Wace LLP. Company insiders that have bought Radius Health stock in the last two years include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland and Jose Carmona. View Insider Buying and Selling for Radius Health.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $15.78.

How big of a company is Radius Health?

Radius Health has a market capitalization of $718.62 million and generates $22.11 million in revenue each year. The biopharmaceutical company earns $-254,230,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Radius Health employs 561 workers across the globe.

What is Radius Health's official website?

The official website for Radius Health is

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]

MarketBeat Community Rating for Radius Health (NASDAQ RDUS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  406 (Vote Outperform)
Underperform Votes:  269 (Vote Underperform)
Total Votes:  675
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel